No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Induction chemotherapy with cisplatin plus gemcitabine in addition to concurrent chemotherapy improves survival for nasopharyngeal carcinoma

byTeddy Guo

September 20, 2022

in StudyGraphics

Reading Time: 1 min read

Combination avelumab and axitinib treatment of advanced type B3 thymoma and thymic carcinoma is promising as second-line treatment after standard therapy.

RelatedReports

Bilateral diagonal earlobe creases associated with increased risk of coronary artery disease

Chronic Disease

Short-course personalized acoustic therapy may increase tinnitus remission in patients with idiopathic sudden sensorineural hearing loss

January 13, 2026

Gastric bypass surgery reduces cardio-metabolic risk factors

Chronic Disease

Endoscopic sinus surgery improves quality of life compared with clarithromycin and placebo in chronic rhinosinusitis

October 28, 2025

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription

The Scan by 2 Minute Medicine®

World Health Organization warns that one in six infections now antibiotic resistant

October 23, 2025

Oncology

Royalty financing deepens exposure to small cell lung cancer revenues

September 8, 2025

Parental input in oncology-related palliation and pain relief for children [Classics Series]

Gender conformity influences use of laxatives and muscle-building products

Risk of myopathy and myalgia among statin users may be small and clinically insignificant

Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial

Impact on socioeconomic status with HFrEF outcomes

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports